Could stem cells help newly diagnosed type 1 diabetes patients?

NCT ID NCT04061746

Ongoing Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether a single infusion of umbilical cord stem cells can safely preserve insulin production in adults newly diagnosed with type 1 diabetes. Sixty participants will receive either the stem cells or a placebo. The main goal is to see if the treatment protects the cells that make insulin, potentially reducing the need for insulin injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord-derived mesenchymal stem cells (MSCs)
What this could lead to: If it works, this could help people with new-onset type 1 diabetes keep making some of their own insulin, reducing the need for daily insulin shots.
What could go wrong: This is an early Phase 1 trial focused on safety, so it is not yet proven to work. The effects may be small or temporary, and there are risks from the infusion itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.